LY06006 not checked

Luye Pharma Group Ltd. · subcutaneous injection of 60 mg

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
None yet
 
Trials
9 active
15 in total · 13 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.”In the company’s words, NCT05853354 on ClinicalTrials.gov
Tested for
Osteoporosis, Postmenopausal
Main trialPhase 3
“this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women with osteoporosis.”In the company’s words, NCT05853354 on ClinicalTrials.gov
Other names
subcutaneous injection of 60 mg · Denosumab
Copy of
Prolia (Amgen)Tested side by side with the original in NCT04973722

Other drugs for Osteoporosis, Postmenopausal

All 3 drugs for Osteoporosis, Postmenopausal

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials15

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 30 Jul 2025 Comparative Efficacy, Safety, PK, and Immunogenicity Study
Phase 3Unknown 30 Sep 2021 A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture
Phase 1Unknown 10 Apr 2021 A Study to Evaluate LY06006 and Prolia in Healthy Adults
Phase 3Ended not given A Phase III, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of BP16 Versus EU-Prolia® in Women with Post- Menopausal Osteoporosis
Phase 2Ended not given NAPO - Novel Approach for Oligospermia
Phase 4Authorised not given The effect of denosumab on muscle and strength and insulin sensitivity
Phase 3/4Authorised not given DEnosumab for the treatment of FIbrous Dysplasia/McCune-Albright Syndrome in adults (DeFiD): a randomized double-blind placebo-controlled trial
Phase 2Ended not given NT-NOA - Novel Treatment of some men with Non-Obstructive Azoospermia Et klinisk interventionsforsøg
Phase 3Authorised not given Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or denosumab to Stereotaxic radiotherapy in the treatment of vertebral metastases (ZOSTER)
Phase 3Authorised not given BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation
Phase 2Authorised not given A 4-way randomized double-blinded migration (RSA), bone density (DXA), and biomarker study assessing adaptive bone changes and implant fixation and longevity of the new Regenerex Porous Titanium Tibial Tray with different adjuvant medical therapies.
Phase 4Authorised not given The DENOCHARCOT trial. Efficacy of treatment with DENOsumab of an acute CHARCOT foot in patients with diabetes. A multicenter, double-blind, randomized, placebo-controlled trial.
Phase 2Authorised not given Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma
Phase 3Ended not given Effects of a single denosumab injection on reduction of total contact cast treatment and consolidation of bone fractures caused by acute Charcot foot in patients with diabetes mellitus (CHARCOT study)
Phase 2Authorised not given Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LY06006

Following is part of Solo: you see every change to LY06006 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in